Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Phase Distribution

Ph early_phase_1

25%

Ph phase_1

50%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (25.0%)

Phase 12 (50.0%)

Phase 21 (25.0%)

Trials by Status

completed375%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133

completedphase_1

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

NCT01527136

completedearly_phase_1

Entolimod, an Adjuvant for Vaccine Augmentation

NCT03063736

withdrawnphase_1

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

NCT01728480

Clinical Trials (4)

Showing 4 of 4 trials

NCT04176133Phase 2

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

Completed

NCT01527136Phase 1

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Completed

NCT03063736Early Phase 1

Entolimod, an Adjuvant for Vaccine Augmentation

Completed

NCT01728480Phase 1

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4